azimexon has been researched along with concanavalin a in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Advani, SH; Gangal, SG; Shetye, MR; Somasundaram, R | 1 |
| Bicker, U; Cortez-Campeao, D; Luckenbach, GA; Modolell, ML; Munder, PG | 1 |
2 other study(ies) available for azimexon and concanavalin a
| Article | Year |
|---|---|
Effect of BM 12 531 on in vitro induction of suppressor cells by concanavalin A in cancer patients and normal healthy donors.
Topics: Aziridines; Azirines; Cells, Cultured; Concanavalin A; Hodgkin Disease; Humans; Leukemia, Myeloid; Lymphocyte Activation; T-Lymphocytes, Regulatory | 1986 |
Immunomodulation by the new synthetic compound BM 12.531, 2-[2-cyanaziridinyl-(1)]-[2-carbamoylaziridinyl-(1)]-propane (azimexone).
Topics: Animals; Antibody Formation; Aziridines; Azirines; Bone Marrow; Concanavalin A; Hypersensitivity, Delayed; Leukocyte Count; Lipopolysaccharides; Lymphocyte Activation; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Phytohemagglutinins; Rats; Sarcoma, Experimental | 1981 |